Plain-English translation of NCT05766800 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment approach for locally advanced non-small cell lung cancer — a type of lung cancer that has spread to nearby tissues but not to distant parts of the body. The study combines (an immune-boosting drug) with chemotherapy, and then evaluates whether surgery or radiation therapy helps patients who respond well to the initial treatment. The goal is to understand if this combination approach can improve survival and outcomes for people with this serious form of lung cancer.
Currently, doctors treat advanced lung cancer with chemotherapy and radiation together, but it's unclear whether adding surgery after the tumor shrinks — if it shrinks enough to be removable — provides additional benefit. This trial aims to answer that important question and help doctors decide the best sequence of treatments for each patient.
You likely qualify if…
You likely don't qualify if…
After enrolling, all participants will receive chemotherapy combined with (the immune-boosting drug) over several weeks. Doctors will then use imaging tests to see if the tumor has shrunk enough to be surgically removed. If it has shrunk enough, you may receive surgery; if not, you will receive radiation therapy instead. You will have regular clinic visits, imaging scans, and blood tests throughout treatment and follow-up to monitor your progress and any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China